Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ( Mark One ) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31 , 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number : 001-35776 ACASTI PHARMA INC . ( Exact name of registrant as specified in its charter ) Québec , Canada ( State or other jurisdiction of incorporation or organization ) 98-1359336 ( I.R.S. Employer Identification Number ) 3009 boul . de la Concorde East , Suite 102 , Laval , Québec , Canada H7E 2B5 ( Address of principal executive offices , including zip code ) Registrant's telephone number , including area code : 450-687-2262 Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Shares , no par value per share Name of each exchange on which registered NASDAQ Stock Market Securities registered pursuant to Section 12 ( g ) of the Act : None Yes ☐ No ☑ Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 ( d ) of the Act . Yes ☐ No ☑ 1